AbbVie and Amgen are two of the largest and most closely watched names in the U.S. biopharmaceutical sector, yet they offer investors meaningfully different profiles. AbbVie, a diversified pharma giant, has spent recent years transitioning beyond its former blockbuster Humira toward newer immunology and neuroscience franchises. Amgen, a pioneering biotechnology company, is navigating its own patent cycle while investing heavily in next-generation obesity and cardiovascular programs. This stock comparison is relevant for income-oriented investors evaluating dividend durability, as well as growth investors assessing which pipeline and relative performance profile appears better positioned in the current market environment.
ABBV, AbbVie Inc., is a global, research-driven biopharmaceutical company with leadership positions across immunology, neuroscience, oncology, and aesthetics. In its most recent quarterly results, the company reported revenue of roughly $17.4 billion, up about 10% year over year, and adjusted earnings per share (EPS) of $3.82, which exceeded analyst expectations. The company also raised its full-year outlook and increased its quarterly dividend by 5.2%, underscoring management's confidence in cash generation.
Recent market activity has been shaped by the continued strength of immunology treatments Skyrizi and Rinvoq, which together more than offset the ongoing decline of Humira as biosimilar competition intensifies. Neuroscience products such as Vraylar and newer migraine therapies have also contributed momentum, while aesthetics remains the portfolio's softer area. Regulatory approvals and a completed acquisition have reinforced a broad, durable growth narrative that has supported positive sentiment in recent weeks.
AMGN, Amgen Inc., is a biotechnology pioneer headquartered in Thousand Oaks, California, with a diversified portfolio spanning general medicine, oncology, rare disease, inflammation, and biosimilars. In its most recent reported quarter, Amgen posted revenue of roughly $10 billion, up about 9% year over year, with adjusted EPS that comfortably beat Wall Street consensus. Management subsequently raised its full-year revenue and earnings guidance.
Amgen's performance has been driven by a set of fast-growing products, including Repatha, Evenity, and rare-disease therapies, which are offsetting erosion in legacy drugs such as Prolia and Enbrel as biosimilars and government pricing policies take effect. The company has also refocused its obesity ambitions around MariTide following the discontinuation of an earlier candidate, with pivotal data expected in the years ahead. While growth remains solid, analyst consensus is more cautious, and the stock carries a relatively rich valuation against mixed forward expectations.
Tickeron maintains a large library of AI trading bots that collectively trade thousands of different tickers, each built with its own trading style, strategy, timeframe, performance record, and universe of stocks. Because market conditions are constantly shifting, only a small subset of these bots is well suited to the current environment. The Trending AI Robots page curates that select group, highlighting the strategies whose recent statistics and setups align best with prevailing market dynamics. For traders comparing names like ABBV and AMGN, this resource offers a practical way to see how quantitative systems are positioning in real time. Explore the Trending AI Robots page to review the currently featured bots and their performance metrics.
The two companies differ most in business-model focus and exposure. ABBV skews toward immunology and neuroscience, with a diversified but more concentrated reliance on a few blockbuster franchises. AMGN spans a broader set of therapeutic areas and adds a biosimilars business and a high-profile obesity pipeline. In terms of scale, AbbVie's market capitalization is roughly double Amgen's, and its dividend-growth trajectory has been more consistent recently, while both offer comparable dividend yields.
On momentum, AbbVie's latest quarter showed accelerating revenue growth with clear guidance raises, whereas Amgen's growth is steadier but faces larger patent-expiration erosion and a more mixed analyst stance. Risk profiles also differ: AbbVie must sustain growth as Humira fades and Skyrizi's growth rate moderates, while Amgen contends with biosimilar pressure on Prolia and Enbrel and the inherent uncertainty of late-stage obesity trials. Sentiment currently appears more constructive around AbbVie's execution, while Amgen trades at a premium relative to its consensus price target.
Based on observable factors such as trend consistency, guidance momentum, dividend durability, and relative positioning, Tickeron's AI framework currently leans toward ABBV over AMGN. AbbVie's combination of double-digit top-line growth, successive guidance increases, and a rising dividend points to steadier near-term momentum and clearer catalysts. Amgen remains a strong, diversified operator, but its larger loss-of-exclusivity overhang and more cautious analyst consensus introduce greater variability. This assessment is probabilistic rather than definitive and reflects current market data rather than a long-term fundamental judgment.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
ABBV saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 03, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 47 instances where the indicator turned negative. In 27 of the 47 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 57%.
The 10-day RSI Indicator for ABBV moved out of overbought territory on November 02, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 43 similar instances where the indicator moved out of overbought territory. In 18 of the 43 cases, the stock moved lower in the following days. This puts the odds of a move lower at 42%.
The Momentum Indicator moved below the 0 level on November 18, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ABBV as a result. In 36 of 76 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 47%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ABBV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 47%.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a +0.57% 3-day Advance, the price is estimated to grow further. Considering data from situations where ABBV advanced for three days, in 222 of 361 cases, the price rose further within the following month. The odds of a continued upward trend are 61%.
ABBV may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 217 of 349 cases where ABBV Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 62%.
The Tickeron SMR rating for this company is 1 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 2 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 61, placing this stock better than average.
The Tickeron Valuation Rating of 4 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: ABBV's P/B Ratio (-86.736) is very low in comparison to the industry average of (-1.421). ABBV has a moderately high P/E Ratio (82.291) as compared to the industry average of (21.700). Projected Growth (PEG Ratio) (0.544) is also within normal values, averaging (5.738). Dividend Yield (0.024) settles around the average of (0.038) among similar stocks. ABBV's P/S Ratio (7.231) is slightly higher than the industry average of (4.033).
The Tickeron Price Growth Rating for this company is 16 (best 1 - 100 worst), indicating outstanding price growth. ABBV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 92 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
AMGN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 24 of 36 cases where AMGN's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 67%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
The 10-day moving average for AMGN crossed bullishly above the 50-day moving average on October 16, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 60%.
Following a +1.07% 3-day Advance, the price is estimated to grow further. Considering data from situations where AMGN advanced for three days, in 194 of 313 cases, the price rose further within the following month. The odds of a continued upward trend are 62%.
The Aroon Indicator entered an Uptrend today. In 147 of 271 cases where AMGN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 54%.
The 10-day RSI Indicator for AMGN moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 47 similar instances where the indicator moved out of overbought territory. In 22 of the 47 cases, the stock moved lower in the following days. This puts the odds of a move lower at 47%.
The Momentum Indicator moved below the 0 level on November 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AMGN as a result. In 29 of 76 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 38%.
The Moving Average Convergence Divergence Histogram (MACD) for AMGN turned negative on November 11, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 19 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 41%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AMGN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 46%.
The Tickeron Profit vs. Risk Rating rating for this company is 4 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 61, placing this stock better than average.
The Tickeron SMR rating for this company is 15 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 35 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 40 (best 1 - 100 worst), indicating steady price growth. AMGN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 79 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (21.297) is normal, around the industry mean (-1.421). P/E Ratio (28.386) is within average values for comparable stocks, (21.700). Projected Growth (PEG Ratio) (2.524) is also within normal values, averaging (5.738). Dividend Yield (0.022) settles around the average of (0.038) among similar stocks. P/S Ratio (5.371) is also within normal values, averaging (4.033).
ABBV | AMGN | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 90 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 4 Undervalued | 79 Overvalued | |
PROFIT vs RISK RATING 1..100 | 2 | 4 | |
SMR RATING 1..100 | 1 | 15 | |
PRICE GROWTH RATING 1..100 | 16 | 40 | |
P/E GROWTH RATING 1..100 | 92 | 35 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ABBV's Valuation (4) in the Pharmaceuticals Major industry is significantly better than the same rating for AMGN (79) in the Biotechnology industry. This means that ABBV’s stock grew significantly faster than AMGN’s over the last 12 months.
ABBV's Profit vs Risk Rating (2) in the Pharmaceuticals Major industry is in the same range as AMGN (4) in the Biotechnology industry. This means that ABBV’s stock grew similarly to AMGN’s over the last 12 months.
ABBV's SMR Rating (1) in the Pharmaceuticals Major industry is in the same range as AMGN (15) in the Biotechnology industry. This means that ABBV’s stock grew similarly to AMGN’s over the last 12 months.
ABBV's Price Growth Rating (16) in the Pharmaceuticals Major industry is in the same range as AMGN (40) in the Biotechnology industry. This means that ABBV’s stock grew similarly to AMGN’s over the last 12 months.
AMGN's P/E Growth Rating (35) in the Biotechnology industry is somewhat better than the same rating for ABBV (92) in the Pharmaceuticals Major industry. This means that AMGN’s stock grew somewhat faster than ABBV’s over the last 12 months.
| ABBV | AMGN | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 42% | 3 days ago 47% |
| Stochastic ODDS (%) | 3 days ago 69% | 3 days ago 60% |
| Momentum ODDS (%) | 3 days ago 47% | 3 days ago 38% |
| MACD ODDS (%) | 3 days ago 57% | 3 days ago 41% |
| TrendWeek ODDS (%) | 3 days ago 49% | 3 days ago 50% |
| TrendMonth ODDS (%) | 3 days ago 64% | 3 days ago 48% |
| Advances ODDS (%) | 12 days ago 61% | 14 days ago 62% |
| Declines ODDS (%) | 4 days ago 47% | 3 days ago 46% |
| BollingerBands ODDS (%) | 3 days ago 62% | 3 days ago 67% |
| Aroon ODDS (%) | 3 days ago 62% | 3 days ago 54% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ABBV’s FA Score shows that 4 FA rating(s) are green while AMGN’s FA Score has 2 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ABBV’s TA Score shows that 4 TA indicator(s) are bullish while AMGN’s TA Score has 5 bullish TA indicator(s).
ABBV (@Pharmaceuticals: Major) experienced а -2.99% price change this week, while AMGN (@Pharmaceuticals: Major) price change was -5.91% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -12.82%. For the same industry, the average monthly price growth was -9.89%, and the average quarterly price growth was -5.74%.
ABBV is expected to report earnings on Feb 03, 2027.
AMGN is expected to report earnings on Feb 09, 2027.
The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
A.I.dvisor indicates that over the last year, ABBV has been loosely correlated with NVS. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if ABBV jumps, then NVS could also see price increases.
| Ticker / NAME | Correlation To ABBV | 1D Price Change % | ||
|---|---|---|---|---|
| ABBV | 100% | +0.94% | ||
| NVS - ABBV | 52% Loosely correlated | -0.50% | ||
| BMY - ABBV | 51% Loosely correlated | +0.79% | ||
| JNJ - ABBV | 51% Loosely correlated | +1.25% | ||
| AMGN - ABBV | 49% Loosely correlated | -0.15% | ||
| GILD - ABBV | 47% Loosely correlated | -0.06% | ||
More | ||||
A.I.dvisor indicates that over the last year, AMGN has been loosely correlated with PFE. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if AMGN jumps, then PFE could also see price increases.
| Ticker / NAME | Correlation To AMGN | 1D Price Change % | ||
|---|---|---|---|---|
| AMGN | 100% | -0.15% | ||
| PFE - AMGN | 51% Loosely correlated | -0.51% | ||
| GILD - AMGN | 48% Loosely correlated | -0.06% | ||
| ABBV - AMGN | 48% Loosely correlated | +0.94% | ||
| BIIB - AMGN | 47% Loosely correlated | +1.00% | ||
| MRK - AMGN | 47% Loosely correlated | +0.69% | ||
More | ||||